A Phase 2/3 interventional study of fexofenadine/Allegra (M016455) in Rhinitis Perennial, sponsored by Sanofi. Completed at 15 sites in Japan. Open to participants aged 6 Months to 11 Years. Per ClinicalTrials.gov, last updated 2013-10-16.
Sponsored by Sanofi · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Primary Objective:
Secondary Objectives:
The study consists of four phases: up to 9-day screening phase, main 4-week treatment phase, up-to 8-week extension phase, and up-to 5-day post-treatment phase.
246 studies on the registry are indexed under Rhinitis; 22 are open to participants now.
This study's enrollment of 100 is above the median of 80 across 187 interventional studies indexed under Rhinitis.
Browse Rhinitis studies →Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Patients between 6 months and 2 years old
Drug: fexofenadine/Allegra (M016455)
Patients between 2 and 11 years (and under 10.5 kg)
Drug: fexofenadine/Allegra (M016455)
Patients between 2 and 11 years (and over 10.5 kg)
Drug: fexofenadine/Allegra (M016455)
Drug page: Fexofenadine
Pharmaceutical form:dry syrup formulation to be suspended in water Route of administration: oral
Number of patients with adverse events
Time frame: 4 weeks
The number of clinically significant abnormalities for laboratory findings
Time frame: 4 weeks
Number of patients with adverse events
Time frame: 12 weeks
The number of clinically significant abnormalities for laboratory findings
Time frame: 12 weeks
Changes from baseline in nasal symptom scores on patient diary
Time frame: 4 weeks
Changes from baseline in nasal symptom severity scores assessed by investigator or subinvestigator
Time frame: week 2 and 4
Pharmacokinetic parameters of fexofenadine at steady state; AUC
Time frame: week 4 and 12
The record gives a start of Oct 2010, a primary completion of Jul 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fexofenadine